Palleon’s phase 1/2 trial of cancer treatment shows promising results
Palleon Pharmaceuticals Inc. has announced positive results from the phase 1/2 trial of its cancer treatment, dubbed ‘SHP2 inhibitor’ (SHP2i). The treatment showed promising efficacy and safety in patients with advanced solid tumors. The SHP2i is designed to target specific proteins in the immune system to fight cancer cells. The trial included patients with various cancer types, including non-small cell lung cancer, colorectal cancer, and ovarian cancer. The treatment was well-tolerated, and patients who received the highest dose of the SHP2i showed a disease control rate of 80%. The company plans to move forward with the development of the treatment and conduct further clinical trials.